Anti-Mouse IL-1b Antibody (B122)
Based on 1 Customer Validation
Anti-Mouse IL-1b Antibody (B122) is an anti-mouse IL-1b IgG monoclonal antibody. Anti-Mouse IL-1b Antibody (B122) enhances ferroptosis and increases levels of reactive oxygen species (ROS) combined with Sulfasalazine (SAS) (HY-14655). Anti-Mouse IL-1b Antibody (B122) can reduce monocyte infiltration and alleviate T cell exhaustion by blocking IL-1β signaling. Anti-Mouse IL-1b Antibody (B122) can be used for researches on cancer and cardiovascular conditions such as oral squamous cell carcinoma (OSCC), glioblastoma (GBM) and heart failure.
For research use only. We do not sell to patients.
- Purity: 99%
- Molecular Weight:150 kDa
-
Storage:
Please store the product under the recommended conditions in the Certificate of Analysis.
To place orders, for customer services and technical support, please contact: MedChemExpress USA
Tel: 609-228-6898 E-mail: [email protected] [email protected]
-
Biological Activity
-
Chemical Information
- Purity & Documentation
- References
-
Help & FAQs
Biological Activity
Armenian Hamster IgG
Mouse
|
IL-1 |
Anti-Mouse IL-1b Antibody (B122) (50 pM, 6-72 h) significantly inhibits the proliferation of various tumor cells combinated with Sulfasalazine (SAS), including SCC1, A375 and MDA-MB231 cells[1].
Anti-Mouse IL-1b Antibody (B122) (50 pM, 24 h) reduces the level of IL-1β and enhances the expression of ferroptosis markers combinated with SAS in SCC1 cells[1].
Anti-Mouse IL-1b Antibody (B122) (50 pM, 24 h) can increase the level of reactive oxygen species and decrease the level of GSH combinated with SAS in SCC1 cells[1].
Anti-Mouse IL-1b Antibody (B122) (50 pM) reverses T cell exhaustion and improves T cell function combinated with 40 % SAS conditioned medium[1].
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
-
Cell Line:SCC1, A375 and MDA-MB231 cells
-
Concentration:50 pM, combinated with SAS (800 μM)
-
Incubation Time:6, 12, 24, 48 and 72 h
-
Result:Significantly reduced the cell viability of three types of cells.
-
Cell Line:SCC1 cells
-
Concentration:50 pM, combinated with SAS (800 μM)
-
Incubation Time:24 h
-
Result:Reduced the level of PTSG2 and IL-1β and increased the level of SLC7A11.
-
Cell Line:SCC1 cells
-
Concentration:50 pM, combinated with SAS (800 μM)
-
Incubation Time:24 h
-
Result:Reduced the level of PTSG2 and IL-1β and increased the level of SLC7A11.
Anti-Mouse IL-1b Antibody (B122) (1 mg, intratumoral injection, once daily, until the endpoint) significantly prolongs the survival period in Ntv-a mice with PDGFB overexpression and p53 silencing[2].
Anti-Mouse IL-1b Antibody (B122) (100 μg, i.p., twice weekly, for 2 weeks) has a protective effect on right ventricular function and pulmonary vascular remodeling in C57BL/6J mice with a heart failure with preserved ejection fraction (HFpEF) model[3].
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
-
Animal Model:Nitrochin (HY-33354) (20 ppm) induced male Sprague-Dawley (SD) rats (4 weeks)[1]
-
Dosage:100 μg/kg, combined with SAS (30 mg/kg)
-
Administration:Intratumoral injection, once every 3 days for 4 weeks
-
Result:Caused only 16.6 % of cases to develop into mild invasive cancer, while 66.6 % of the control group had moderate invasive cancer.
Significantly inhibited tumor development with the lowest HE score.
Reduced the expression of SLC7A11 and IL-1β and increased the expression of PTGS2.
Reduced Ki67+ cells.
-
Animal Model:Ntv-a mice with a PDGFB glioblastoma (GBM) model(8-12 weeks)[2]
-
Dosage:1 mg
-
Administration:Intratumoral injection, once daily, until the endpoint
-
Result:Significantly prolonged the survival of PDGFB GBM mice (median survival extended from 40 days to 47 days).
Reduced tumor associated macrophage (TAMs) infiltration.
Reduced the expression of T cell exhaustion markers (such as PD-1).
-
Animal Model:L-NAME (HY-18729) (0.5 g/L) and high-fat diet (60 % lipid) administrated C57BL/6J mice (8 weeks)[3]
-
Dosage:100 μg
-
Administration:Intraperitoneal injection (i.p.), twice weekly, for 2 weeks
-
Result:Significantly reduced the level of IL-1β in lung tissue.
Reduced elevated right ventricular systolic pressure and pulmonary small vessel muscularization.
Had no significant effect on weight changes and right ventricular end diastolic pressure.
Unconjugated
The product can be reconstituted/diluted with sterile PBS or saline.
-
Product Image
in vivo IL-1β neutralization; in vitro IL-1β neutralization; ELISA
Chemical Information
-
Appearance Liquid
-
Molecular Weight 150 kDa
-
Color Colorless to light yellow
-
SMILES
[Anti-Mouse IL-1b Antibody (B122)]
-
Formulation
Please refer to the lot-specific COA for specific buffer information.
-
Storage
Please store the product under the recommended conditions in the Certificate of Analysis.
Purity & Documentation
-
Data Sheet (267 KB)
-
SDS (251 KB)
- English - EN (251 KB)
- Français - FR (251 KB)
- Deutsch - DE (251 KB)
- Norwegian - NO (251 KB)
- Español - ES (251 KB)
- Swedish - SV (251 KB)
- Italian - IT (251 KB)
- Korean - KR (251 KB)
- Portuguese - PT (251 KB)
-
Inhibitory Antibodies User Guide (603 KB)
References
[1]. Zhou R, et al. Sulfasalazine combined with anti-IL-1β mAb induces ferroptosis and immune modulation in oral squamous cell carcinoma. Cell Mol Life Sci. 2025 May 28;82(1):216. [Content Brief]
[2]. Chen Z, et al. A paracrine circuit of IL-1β/IL-1R1 between myeloid and tumor cells drives genotype-dependent glioblastoma progression. J Clin Invest. 2023 Nov 15;133(22):e163802. [Content Brief]
[3]. Agrawal V, et al. Myeloid Cell Derived IL1β Contributes to Pulmonary Hypertension in HFpEF. Circ Res. 2023 Nov 10;133(11):885-898. [Content Brief]
Calculators
Concentration (start) × Volume (start) = Concentration (final) × Volume (final)
Anti-Mouse IL-1b Antibody (B122) Related Classifications
HY-P99139 Related Classifications
Powered by Bioz